ERBB2 and glioblastoma: In the clinical trial of HER2-CAR VSTs for progressive glioblastoma, 8 out of 17 patients experienced clinical benefits, with 1 patient having a partial response lasting over 9 months, and 7 patients maintaining stable disease for 8 weeks to 29 months.